Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma

Ann Oncol. 2010 Jul;21(7):1563-1565. doi: 10.1093/annonc/mdq299.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Benzenesulfonates / adverse effects*
  • Carcinoma, Renal Cell / complications*
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / pathology
  • Erythema Multiforme / chemically induced*
  • Erythema Multiforme / diagnosis
  • Erythema Multiforme / drug therapy
  • Female
  • Humans
  • Kidney Neoplasms / complications*
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / secondary
  • Male
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / adverse effects*
  • Sorafenib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib